Table 1.

Mono and combined drug therapy in RA.

Mono drug therapy	Targets
Tocilizumab, Sarilumab	IL-6⁹⁸
Etanercept, Infliximab, Adalimumab, Golimumab, and Certolizumab Pegol	TNF^65,98
Tofacitinib (RA-FLS), Baricitinib, Itacitinib	JAK^98,99
Secukinumab	IL-17⁹⁸
Andecaliximab, Celastrol (RA-FLS)	MMP9^98,100,101
Imatinib	PDGF^16,102
Methotrexate	IL1B, PDGF, NFKB^103,104
Anakinra	IL1B¹⁰⁵

Combined drug therapy	Targets
Methotrexate + Sarilumab (or Tocilizumab)	NFKB, PDGFA, IL1B targeted by Methotrexate + IL-6 targeted by Sarilumab^106,107
Methotrexate + Cyclosporine	NFKB, PDGFA, IL1B targeted by Methotrexate + Calcineurin targeted by Cyclosporine^108,109
Methotrexate + Azathioprine	NFKB, PDGFA, IL1B targeted by Methotrexate + RAC1 by Azathioprine^110,111
Methotrexate + Hydroxychloroquine	NFKB, PDGFA, IL1B targeted by Methotrexate + TLRs targeted by hydroxychloroquine^112,113
Methotrexate + Infliximab or Golimumab	NFKB, PDGFA, IL1B targeted by Methotrexate + TNF targeted by Infliximab/Golimumab¹¹⁴
TNF inhibitor + Abatacept	TNF + CD80^, CD86, CD28 targeted by Abatecept^115,116
TNF inhibitor + Anakinra	TNF + IL-1 targeted by Anakinra¹¹⁵
Abatacept + Anakinra	CD80, CD86, CD28 targeted by Abatecept + IL-1 targeted by Anakinra¹¹⁵

*Absent in the model.